Autolus Therapeutics (AUTL)

Autolus Therapeutics plcis a clinical-stage biopharmaceutical company developing next-generation, programmed T cell therapies for the treatment of cancer. Using a broad suite of proprietary and modular T cell programming technologies, the company is engineering precisely targeted, controlled and highly active T cell therapies that are designed to better recognize cancer cells, break down their defense mechanisms and eliminate these cells. Autolus has a pipeline of product candidates in development for the treatment of hematological malignancies and solid tumors.

Company profile

Ticker

AUTL

Exchange

NASDAQ

Website

www.autolus.com

CEO

Christian Martin Itin

Incorporated

United Kingdom

Location

United Kingdom

Fiscal year end

Dec 31

Sector

Manufacturing > Biological Product (except Diagnostic) Manufacturing

Industry (SIC)

Biological Products, (No Diagnostic Substances)

AMGEN • Gilead Sciences • Biogen • Qiagen • Moderna • BioNTech SE • Sana Biotechnology • Ginkgo Bioworks • Bio-Techne • Denali Therapeutics ...

Former names

Autolus Therapeutics Ltd

SEC CIK

0001730463

Corporate docs

Articles of Incorporation & Bylaws

Underwriting Agreements

Plans of Reorganization

Indentures

Material Contracts & Credit Agreements

Subsidiaries Lists

AUTL stock data

1M 1Y 5Y

News

From Benzinga Pro

Needham Maintains Buy on Autolus Therapeutics, Lowers Price Target to $12

5 Aug 22

Needham analyst Gil Blum maintains Autolus Therapeutics (NASDAQ:AUTL) with a Buy and lowers the price target from $13 to $12.

Autolus Therapeutics Earlier Reported Q2 EPS $(0.46) Beats $(0.51) Estimate

4 Aug 22

Autolus Therapeutics (NASDAQ:AUTL) reported quarterly losses of $(0.46) per share which beat the analyst consensus estimate of $(0.51) by 9.8 percent. This is a 2.13 percent increase over losses of $(0.47) per share from

Recap: Autolus Therapeutics Q2 Earnings

4 Aug 22

Autolus Therapeutics (NASDAQ:AUTL) reported its Q2 earnings results on Thursday, August 4, 2022 at 07:00 AM. Here's what investors need to know about the announcement.

Earnings Scheduled For August 4, 2022

4 Aug 22

Stocks That Hit 52-Week Lows On Wednesday

15 Jun 22

Press releases

From Benzinga Pro

Autolus Therapeutics Reports Second Quarter 2022 Financial Results and Operational Progress

4 Aug 22

LONDON, Aug. 04, 2022 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (NASDAQ:AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced its operational and

Correction - Autolus Therapeutics to Report Second Quarter 2022 Financial Results on August 4, 2022

21 Jul 22

In the previous version the link to register for the conference call was incorrect – this press release contains the correct link to register for the call, and replaces the earlier version LONDON, July 21, 2022 (GLOBE

Autolus Therapeutics to Participate in William Blair's Biotech Focus Conference 2022, New York, July 12 – 13, 2022

6 Jul 22

LONDON, July 06, 2022 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (NASDAQ:AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announces that management will

Autolus Therapeutics Presents Clinical Data Updates at the European Hematology Association Congress

10 Jun 22

Autolus to hold Annual General Meeting (AGM) of Shareholders on Tuesday, June 28, 2022

31 May 22

Analyst ratings and price targets

Last 3 months

Average target

$11.50

Low target

$11.00

High target

$12.00

Calendar

10 Mar 22

13 Aug 22

31 Dec 22

Financial summary

Financial statements Chart AUTL financial data

Quarter (USD)	Dec 21	Dec 20	Dec 19	Dec 18
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Annual (USD)	Dec 21	Dec 20	Dec 19	Sep 18
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Cash burn rate (est.)	Burn method: Change in cash		Burn method: Operating income		Burn method: FCF (opex + capex)
	Last Q	Avg 4Q	Last Q	Avg 4Q	Last Q	Avg 4Q
Cash on hand (at last report)		310.68M		310.68M	310.68M	310.68M
Cash burn (monthly)		2.97M		5.82M	(no burn)	4.41M
Cash used (since last report)		22.1M		43.27M	n/a	32.82M
Cash remaining		288.57M		267.4M	n/a	277.86M
Runway (months of cash)		97.1		46.0	n/a	63.0

Beta Read what these cash burn values mean

Financial data from company earnings reports.

Institutional ownership, Q1 2022

AUTL institutional ownership history Ownership history

80.6% owned by funds/institutions

13F holders	Current	Prev Q	Change
Total holders	67	73	-8.2%
Opened positions	8	23	-65.2%
Closed positions	14	9	+55.6%
Increased positions	17	18	-5.6%
Reduced positions	26	18	+44.4%

13F shares	Current	Prev Q	Change
Total value	1.2B	405.77M	+194.9%
Total shares	73.3M	72.57M	+1.0%
Total puts	0	43.6K	EXIT
Total calls	44.2K	86.5K	-48.9%
Total put/call ratio	–	0.5	–

Largest owners	Shares	Value	Change
BX Blackstone	17.99M	$75M	0.0%
PPF Capital Partners Fund B.V.	14.61M	$94.69M	0.0%
Syncona Portfolio	7.35M	$38.13M	0.0%
Nantahala Capital Management	4.35M	$18.12M	+6.6%
Frazier Life Sciences Management	3.75M	$15.62M	NEW
Citadel Advisors	3.51M	$14.65M	+106.9%
Arix Bioscience	3.32M	$24.2M	0.0%
Frazier Life Sciences Public Fund	3.01M	$18M	0.0%
Polygon Management	2.83M	$11.78M	+4.7%
Schroder Investment Management	1.67M	$7.08M	0.0%

Largest transactions	Shares	Bought/sold	Change
Frazier Life Sciences Management	3.75M	+3.75M	NEW
Frazier Management	0	-3.75M	EXIT
Capital World Investors	1.06M	-1.9M	-64.1%
Citadel Advisors	3.51M	+1.81M	+106.9%
LGT Capital Partners	500K	+500K	NEW
DAFNA Capital Management	496.15K	+496.15K	NEW
Deep Track Capital	382.56K	+382.56K	NEW
Nantahala Capital Management	4.35M	+268.82K	+6.6%
SG Americas Securities	0	-250.82K	EXIT
GS Goldman Sachs	375.51K	+222.09K	+144.8%

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

Financial report summary

Competition

Bristol-Myers Squibb • AMGEN • Celgene • Gilead Sciences • Seagen • Alaunos Therapeutics • Novartis • Precigen • Bellicum Pharmaceuticals • Fate Therapeutics

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. sophomore Avg

New words: Aachen, absorb, Academy, analyze, analyzing, anatomic, antibiotic, arose, ARUP, ATM, Authorisation, Autobahn, autoleucel, AVEO, Axogen, behaviour, Biomedical, BioNJ, Biopharma, bispecific, Blackstone, Bonn, Boston, Braendle, Brent, Breyanzi, BS, BV, BX, cardiac, carve, cascade, categorized, CCR, classic, classical, CMC, contemplation, costimulatory, counterparty, Curie, cut, daily, Dainippon, deactivation, deadlock, debilitate, Denver, dialled, digit, disbursement, disbursing, Disc, displace, downside, dSHP, Edgar, effector, eighteen, embedded, encumber, encumbering, faster, fell, fifteen, FKBP, floor, foot, Forge, fourteen, Franchise, FRB, freestanding, GMP, GP, guaranty, heterodimerise, hierarchy, Hodgkin, ID, IFN, ImClone, imputed, Journal, Juno, LabCorp, LAVA, Los, LP, Lugano, lymphodepletion, MBA, Melinta, Merck, metabolic, mid, Moderna, ModernaTX, Monogram, Nanostring, necessitate, neutropenia, NYSE, obecabtagene, opted, outset, paradigm, pathology, Pfizer, pharmacodynamic, PhRMA, poised, Portola, PR, proliferative, Purdue, quoted, ready, rearm, recertification, Reef, rental, repeat, reprogram, Rice, safest, Sanofi, Schering, SDPO, seasoned, speed, stably, steering, straight, stream, Strongbridge, Stroudsburg, Sumitomo, SVP, TetCAR, TG, TGF, Theravance, thinly, tumour, tuneable, Ulm, unamortized, unencrypted, unobservable, urology, VBI, Verastem, Vertex, Village, VP, wait, Whitewood

Removed: Backsolve, book, British, matching, OPM, reconciling, retroactively, scenario, Tabular, unlevered

From filing 20-F 2021 FY

Financial reports

20-F

2021 FY

Annual report (foreign)

10 Mar 22

20-F

2020 FY

Annual report (foreign)

4 Mar 21

20-F/A